Key result
Patient characteristics in primary progressive multiple sclerosis challenge phase 2 and 3 trial designs, particularly for testing therapeutics directed at neuroprotection and repair.
This review highlights the importance of patient selection and trial design in developing therapeutics for primary progressive multiple sclerosis.
Answers are grounded in this paper and cite their sources.
May guide PPMS trial enrollment; leaves open optimal design for progressive disease.
The last several decades have witnessed considerable progress in our understanding of the pathogenesis, refining diagnostic criteria, and identifying therapies of value for modifying the course of relapsing forms of multiple sclerosis. While the pace of progress has lagged for those with progressive phase disease, this now seems to be changing. This review considers those characteristics of patients with primary progressive multiple sclerosis that may contribute to phase 3 trial success and identifies some of the thorny issues that remain ahead. The larger of the studies conducted thus far have sequentially informed our understanding of "pure" primary progressive disease, and also challenge both phase 3 and especially phase 2 trial designs and participant selection for investigations going forward. This may have particular relevance for testing therapeutics directed at neuroprotection and repair in the face of ongoing progression regardless of trial participant categorization using current conventional disease phenotypes.
No takes yet. Share an insight, caveat, or question.
Jerry S. Wolinsky (2017) conducted a review in Primary progressive multiple sclerosis. Patient characteristics in primary progressive multiple sclerosis challenge phase 2 and 3 trial designs, particularly for testing therapeutics directed at neuroprotection and repair.
Synapse has enriched 10 related papers. Consider them for comparative context: